Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...

AstraZeneca Announces Symbicort Is Now Available In The U.S. U.S. Asthma Sufferers Now Have a New Choice of Combination Therapy to Help Achieve Asthma Control LONDON ...

Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...

hands holding a smart phone How effective are add-on devices for pressurized metered-dose inhalers in helping patients with asthma to avoid poor outcomes associated with incorrect inhaler use? In ...

If you're having an asthma attack, you assume that with each puff of your inhaler you are getting relief. But, in many cases, it seems inhalers are being used long after they have run out of ...

a Adapted from Fromer L, Goodwin E, Walsh J. Customizing inhaled therapy to meet the needs of COPD patients. Postgrad Med. 2010; 122:83–93, updated using U.S. Food ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients who ...

LONDON, UK, 7 March 2011 - SkyePharma PLC (LSE: SKP) today announces that AstraZeneca has informed it of a decision to discontinue production of PULMICORT (budesonide) 100 and 200 µg/dose HFA pMDI ...

(RTTNews) - British drug major AstraZeneca is joining with U.S. Technology major Honeywell to develop next-generation respiratory inhalers that use near-zero global warming potential or GWP ...